We developed a real-time PCR assay combined with melting curve analysis for rapidly genotyping quinolone-resistant determining regions (QRDR) of topoisomerase genes in Streptococcus pneumoniae. This assay was not only accurate for the screening of fluoroquinolone (FQ) resistance but also relevant as an early-warning system of detecting pre-existent single QRDR mutations.
Streptococcus pneumoniae is the leading cause of community-acquired pneumonia (CAP) and is also responsible for substantial morbidity and mortality worldwide. Anti-pneumococcal fluoroquinolones (FQs), such as levofloxacin, gatifloxacin, gemifloxacin, and moxifloxacin, have greater activity against S. pneumoniae, and several are now approved for empirical treatment of CAP 2, 18) . However, recent reports have already noted an increase in the prevalence of FQ-resistant pneumococci 4, 11, 27) . FQ resistance in S. pneumoniae often involves mutation in the quinolone resistance-determining regions (QRDR) of the parC gene and the gyrA gene, which encode subunits of topoisomerase IV and DNA gyrase 9, 14, 15, 23) . Recent clinical treatment failures of FQ-resistant pneumococcal pneumonia have been reported to be due to strains which acquired FQ resistance as a result of QRDR stepwise-mutations 7, 10, 24) . Rapid detection of QRDR mutations is required and it may constitute a more reliable approach than the current phenotypic method, which can represent susceptibility but cannot detect the potential of S. pneumoniae to harbor resistance. PCR-based techniques, such as PCR-restriction fragment length polymorphism 1, 16, 20) , single-strand comformational polymorphism 16) , and PCR-oligonucleotide ligation 3) have been developed to detect QRDR mutations, however, these techniques are not appropriate for practical use as they are complicated and time-consuming. More recently, real-time PCR method combined with melting curve analysis (PCR-MCA) have been reported to be successful in the detection of key-gene mutations associated with drug resistance in various microorganisms 13, 25, 26) .
The aim of the present study was to develop and to validate a rapid single-step PCR-MCA assay for genotyping S. pneumoniae strains, which targeting four QRDR positions (Ser79 and Asp83 of the parC gene and also Ser81 and Gly85 of the gyrA gene) that are most frequently associated with FQ resistance 4, 8, 21) . Seventy-two S. pneumoniae clinical isolates were used; they consisted of 22 levofloxacin -resistant strains with minimum inhibitory concentration (MIC) of ≥ 8 g/ml and 50 LVX-susceptible strains with MIC of ≤ 2 g/ml 6) . Twenty-two resistant strains were collected from Nagasaki University Hospital (7), Sapporo Medical University School of Medicine (5) 28, 29) , and the Levofloxacin Surveillance Group (10) 27) in Japan. Fifty susceptible strains were isolated at Nagasaki University Hospital. Identification of S. pneumoniae was confirmed by optochin susceptibility 12) and by the autolysine gene 22) . The MICs of ciprofloxacin (CIP), levofloxacin (LVX), gatifloxacin (GAT), and moxifloxacin (MXF) were determined by a broth dilution method 5, 6) . S. pneumoniae ATCC 49619 was used for quality control.
DNA was extracted from each strain using a QIA amp® DNA Mini kit (QIAGEN, Hilden, Germany). All of the designed oligonucleotides are shown in Table 1 . These refer to the known sequence of the parC and gyrA genes, which were derived from GenBank accession no. AF170996 and no. AF053121, respectively. PCR was performed in a total volume of 20 μl containing 5 μl of DNA template (average 5 ng/reaction), 2 μl of LightCycler® FastStart Reaction Mixture (Roche Diagnostics, Basel, Switzerland), 3mM MgCl 2 , 0.2 μM each probes, and 0.5 μM each primers. Thermal cycling was performed with an initial hold for 10 min at 95ºC, followed by 35 cycles of 5 sec at 95ºC, 9 sec at 55ºC and 12 sec at 72ºC. Melting curve was generated by cooling to 35ºC for 10 sec, followed by heating to 70ºC at a rate of 0.2ºC/s.
The PCR-MCA assay was performed using LightCycler® analysis software 3.5 (Roche Diagnostics, Basel, Switzerland). The total assay time was approximately 1 hr. PCR amplification products of 72 strains were all directly sequenced at the nucleotide level using (Figure 1-A) . Similarly, the MCA at parC codon 83 produced three different peaks (Figure 1-B (Table 2) .
MCA of LVX-susceptible S. pneumoniae and sequence analysis of QRDRs.
Forty-seven of the 50 LVX-susceptible S. pneumoniae strains had similar T m values to that of the wild-type strain. The mean T m s of the 47 strains were 60.4ºC (CV: 0.41%) at parC codon79, 56.7ºC (CV: 0.52%) at parC codon83, 56.5ºC (CV: 0.87%) at gyrA codon81, and 56.7ºC (CV: 0.34%) at gyrA codon85, and sequencing results comfirmed that these are in fact wild-type strains. Two of the remaining three strains had T m s of 49.8ºC and 50.0ºC, which were lower than that (60.4ºC) of the wild-type strain at parC codon79, while the other strain had a T m of 48.8ºC, which differed from the wild-type strain (56.7ºC) at parC codon83.
Indeed, direct sequencing revealed that the former two strains had a TTT [237] [238] [239] (Ser79Phe) mutation, while the latter strain had a AAT 249-251 (Asp83Asn) mutation in the parC gene.
Comparison of the outcomes between conventional phenotyping and MCA genotyping.
We compared the ability of the present PCR-MCA assay to detect FQ susceptibility in 72 S. pneumoniae strains with that of conventional phenotypic method, as shown in Figure 2 and Table 3 . All of the 47 LVX-susceptible strains with no mutations had susceptibility MICs of ≤ 2g/ml, while 22 of the remaining 25 mutation-containing strains (88%) had resistance MICs of ≥ 8 g/ml (Figure 2 -B, Table 3-B) . Interestingly, the mutation profiles of the QRDRs in the parC and gyrA genes revealed a close relationship between MIC level and the number of QRDR mutations. We observed that 6 out of the 9 strains with a single QRDR mutation were highly resistant to LVX (Figure 2 -B, Table 3-B) . This can be explained by the fact that 3 out of the 6 strains harbored additional parE mutation and an active efflux, 2 out of the 6 strains harbored additional parE mutation, and the remaining strain harbored additional gyrB mutation (data not shown). Compared with the conventional phenotypic method, the diagnostic sensitivity and specificity of the PCR-MCA assay to detect FQ non-susceptible strains was 100% (25/25) and 100% (47/47) for CIP, 100% (22/22) and 94% (47/50) for LVX, 100% (21/21) and 92% (47/51) for GAT, and 100% (15/15) and 82% (47/57) for MXF.
Assuming QRDR mutation provides a positive diagnosis of the presence of FQ-nonsusceptible S. pneumoniae, this assay is particularly useful because it has a negative predictive value of 100% for all four FQs, and a positive predictive value of 100% for CIP, LVX, and GAT, and 93.7% for MXF (Figure2, Table 3 ).
The discrepancies observed in the specificity of the assay were instructive because the conventional phenotypic method failed to pick up strains which have high proportions of a single QRDR mutation. Several reports have noted that a significant number of isolates which already have a single mutation but are still considered fully susceptible 8, 21) . Although our study lacks a collection of moderately FQ-resistant (LVX MIC of 2g/ml or 4g/ml) S. pneumoniae, Lim et al. 17) have reported that about 60% of S. pneumoniae isolates with a LVX MIC of 2 g/ml carry pre-existent parC mutations. Typically or generally, stepwise mutation starts with the parC gene, which frequently leads to secondary mutations in the gyrA gene, eventually resulting in highly resistance to all FQs 19) . This has been also supported by clinical reports of a FQ-susceptible S. pneumoniae strain carrying a first-step mutation that evolved into a second-step QRDR mutation during FQ treatment, resulting in treatment failure 7) . We emphasize the clinical importance of the detection of first-step QRDR mutations either in gyrA or parC when attempting to predict evolution into FQ resistance. There are some limitations of this assay that remain to be ironed out; for instance, any mutations outside of the sensor probe would be undetectable. Resistance as a result of other mechanisms (such as parE and gyrB mutation, and efflux) can also not be detected. However, these mechanisms provide resistance potential but are not conclusive indicators of highly resistance to FQ compared with parC and gyrA mutation 8, 21) .
In conclusion, the PCR-MCA assay was easily and quickly performed and had an accuracy at least as satisfactory as that of the conventional phenotypic method. Moreover, single QRDR mutations which harbored potential of FQ resistance could be detected. This assay is also useful for surveillance studies in the screening of FQ resistance as an alternative to DNA nucleotide sequencing. The application of this novel method would be a valuable tool to achieve rapid screening of QRDR mutations and as an early warning system for the emergence of FQ-resistant S. pneumoniae. tables represents number of strains. Abbreviations: S; susceptible, I; intermediate, and R; resistant. The CLSI MIC breakpoints are as follows: LVX (susceptible <2g/ml, intermediate 4g/ml, and resistant >8g/ml), GAT (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml), and MXF (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml). The breakpoint standard for CIP was obtained from interpretive guideline supplied by the Japanese Society of Chemotherapy (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml). are as follows: LVX (susceptible <2g/ml, intermediate 4g/ml, and resistant >8g/ml), GAT (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml), and MXF (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml). The breakpoints standard for CIP was obtained from interpretive guideline supplied by the Japanese Society of Chemotherapy (susceptible <1g/ml, intermediate 2g/ml, and resistant >4g/ml). 
